Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XS025
- Development stage
- Preclinical
- Lead developer
- Xspray Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
XS025 is an amorphous, non-crystalline formulation of cabozantinib developed by Xspray Pharma using its proprietary HyNap platform. As a multi-kinase inhibitor, it targets MET, VEGFR2, and RET, which are critical drivers in tumor angiogenesis and progression. The HyNap technology is employed to create a stable amorphous version of the drug substance, aiming to improve the pharmacokinetic profile and solubility compared to the crystalline form found in the reference product, Cabometyx. XS025 is currently being developed for the treatment of renal cell carcinoma and other solid tumors, with the developer preparing to advance the candidate into clinical studies.
- Other names
- cabozantinib amorphousHyNap cabozantinib
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)MET (Mesenchymal-epithelial transition factor receptor)RET (Rearranged during transfection receptor tyrosine kinase)MST1R (Recepteur d'origine nantais)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on XS025.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XS025.